Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Department of Justice
Fuji
Covington
Harvard Business School
Moodys
AstraZeneca
Teva
Boehringer Ingelheim
Federal Trade Commission

Generated: April 26, 2018

DrugPatentWatch Database Preview

Doxylamine succinate; pyridoxine hydrochloride - Generic Drug Details

« Back to Dashboard

What are the generic sources for doxylamine succinate; pyridoxine hydrochloride and what is the scope of doxylamine succinate; pyridoxine hydrochloride freedom to operate?

Doxylamine succinate; pyridoxine hydrochloride
is the generic ingredient in four branded drugs marketed by Duchesnay, Actavis Labs Fl Inc, Par Pharm Inc, and Sanofi Aventis Us, and is included in five NDAs. There are five patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Doxylamine succinate; pyridoxine hydrochloride has ninety-six patent family members in forty-two countries.

There are fourteen drug master file entries for doxylamine succinate; pyridoxine hydrochloride. One supplier is listed for this compound.
Summary for doxylamine succinate; pyridoxine hydrochloride
Pharmacology for doxylamine succinate; pyridoxine hydrochloride

US Patents and Regulatory Information for doxylamine succinate; pyridoxine hydrochloride

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sanofi Aventis Us BENDECTIN doxylamine succinate; pyridoxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 010598-002 Approved Prior to Jan 1, 1982 DISCN No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Par Pharm Inc DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE doxylamine succinate; pyridoxine hydrochloride TABLET, DELAYED RELEASE;ORAL 208518-001 Dec 6, 2017 AB RX No No ➤ Sign Up ➤ Sign Up ➤ Sign Up
Duchesnay BONJESTA doxylamine succinate; pyridoxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209661-001 Nov 7, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Duchesnay BONJESTA doxylamine succinate; pyridoxine hydrochloride TABLET, EXTENDED RELEASE;ORAL 209661-001 Nov 7, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Farmers Insurance
Deloitte
QuintilesIMS
Teva
Julphar
Mallinckrodt
Baxter
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.